Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular (NASDAQ: LMAT) delivers innovative medical devices for vascular surgeons worldwide. This page provides centralized access to official announcements, financial disclosures, and strategic developments from the leader in peripheral vascular disease solutions.
Investors and medical professionals will find timely updates on product launches, regulatory milestones, and financial results. Track advancements in carotid shunts, vascular grafts, and other devices critical to open vascular surgery.
Our curated news collection enables you to monitor LMAT's progress in addressing circulatory challenges through cutting-edge technologies. Discover updates on manufacturing expansions, clinical study outcomes, and partnerships shaping the future of vascular care.
Bookmark this page for direct access to verified information about LeMaitre Vascular's surgical innovations and market leadership. Check regularly for new developments impacting the medical device sector and patient care standards.
LeMaitre (Nasdaq:LMAT) reported Q1 2021 results showing sales of $35.9 million, a 17% increase year-over-year, despite a 5% organic decline. Net income reached $5.9 million, up 87%, with earnings per share of $0.28, also an 83% increase. Sales in the Americas and Asia/Pac grew significantly, while Europe/Middle East/Africa experienced a decline. The company declared a quarterly dividend of $0.11 per share, to be paid on June 3, 2021. For Q2 2021, LeMaitre projects sales between $37 million and $40 million, with a gross margin of 66.7%. Their share repurchase program has been authorized for up to $15 million.
LeMaitre Vascular announced its participation in two upcoming investor conferences in May 2021. David Roberts, President, will present at the 7th Annual Truist Securities Life Sciences Summit on May 4, 2021. He will also be featured at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 9:00 AM EDT. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. The firm develops vascular devices tailored for vascular surgeons. More information is available at lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its Q1 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for 5:00 PM EDT on the same day to discuss the financial results, business highlights, and outlook. Interested parties can access the call via phone or a live webcast. LeMaitre is known for its vascular devices, addressing the needs of vascular surgeons and catering to a global patient base affected by peripheral vascular disease.
LeMaitre Vascular announced that CFO JJ Pellegrino will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 AM EDT. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For further information, visit www.lemaitre.com.
LeMaitre (Nasdaq: LMAT) reported strong Q4 2020 results, with sales of $37.5 million, a 24% increase year-over-year. Operating income surged 94% to $9.5 million, resulting in a net income of $7.0 million and earnings of $0.34 per diluted share. Debt was reduced by $21.5 million, improving the balance sheet. Despite gross margin slightly declining to 65%, the company achieved record sales driven by acquisitions and strong performance in the Americas. For Q1 2021, LeMaitre projects sales between $33.8 and $36.8 million, with an expected earnings per share of $0.24 to $0.31.
LeMaitre Vascular (Nasdaq:LMAT) is set to participate in four key investor conferences in February and March 2021. David Roberts, President, will present at:
- SVB Leerink's Global Healthcare Conference on February 26, 2021, at 8:40 AM EST
- Barclays Global Healthcare Conference on March 9, 2021, at 1:50 PM EST
- 33rd Annual Roth Conference on March 15, 2021, on demand
- Oppenheimer's Healthcare Conference on March 16, 2021, at 3:10 PM EDT
LeMaitre Vascular specializes in devices and services for peripheral vascular disease, helping over 200 million people globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will release its fourth quarter 2020 financial results on February 25, 2021, post-market. A conference call is scheduled for the same day at 5:00 PM ET to discuss results and company outlook. Investors can dial in or access the call via a webcast at www.lemaitre.com/investor. LeMaitre is known for its devices addressing peripheral vascular disease, a condition impacting over 200 million individuals globally, and offers a diversified product portfolio for vascular surgeons.
LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two upcoming investor conferences in January 2021. CFO JJ Pellegrino will present at the 23rd Annual Needham Virtual Growth Conference on January 11, 2021, at 11:30 AM ET, and at the Sidoti Winter 2021 Investor Conference on January 14, 2021, at 10:45 AM ET. The company, which specializes in devices for treating peripheral vascular disease, aims to inform and engage investors about its market position and growth strategies.
LeMaitre Vascular announced that President David Roberts will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:25 PM ET. The company specializes in devices and services for treating peripheral vascular disease, which impacts over 200 million people globally. LeMaitre develops both disposable and implantable vascular devices, focusing on the needs of vascular surgeons.
LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two investor conferences this November. David Roberts, President, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 8:00 AM ET. Meanwhile, JJ Pellegrino, Chief Financial Officer, is set to speak at the Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. LeMaitre Vascular specializes in devices for treating peripheral vascular disease, serving over 200 million people globally.
FAQ
What is the current stock price of Lemaitre Vasculr (LMAT)?
What is the market cap of Lemaitre Vasculr (LMAT)?
